Skymount Medical, using research developed at Louisiana State University (LSU), has launched Inhibinol™ – a dietary supplement formulated with the help of artificial intelligence (AI) to support the immune system, critical antioxidant functions, and overall cardiovascular health. The launch arrives as the interest in dietary supplements for improved health grows exponentially, with a global market for such products expected to hit a record value of 306.8B by 2026.
“The pandemic has created a lot of uncertainty surrounding immune system health,” said Chris Galliano, Chief Technology Officer of Skymount Medical. “AI-derived Inhibinol™ is the first product of its kind and a prime example of a smarter generation of dietary supplements. We hope the product will empower people to take charge of and have more confidence in their own health and wellness. In essence, you can think of Inhibinol™ as a personal health shield.”
Designed to be a highly effective blend of natural extracts, essential vitamins and minerals, Inhibinol™ was discovered and developed by the platform called DeepDrug™. By leveraging AI, DeepDrug™ can score and correlate millions of molecular combinations at a speed unattainable through traditional research methods.
The DeepDrug™ formulations are resulting in novel products, such as Inhibinol™, intended to help correct the vitamin/mineral imbalance in the body. Inhibinol™ also relies on familiar ingredients, such as ginseng and chamomile, to fight free radicals, which can negatively impact cellular function and overall immune health.
DeepDrug™ was created in 2012 by the LSU research team and is led by Supratik Mukhopadhyay, associate professor in the LSU Department of Computer Science and an expert on health applications of AI. To date, his discoveries have been awarded three U.S. patents, with at least four more currently pending.
Learn more about Skymount Medical here.
Click here to learn more about Inhibinol™.